Lower blood levels of isavuconazole in critically ill patients compared with other populations: possible need for therapeutic drug monitoring
Malgorzata Mikulska,Monica Melchio,Alessio Signori,Nadir Ullah,Franca Miletich,Chiara Sepulcri,Alessandro Limongelli,Daniele Roberto Giacobbe,Elisa Balletto,Chiara Russo,Laura Magnasco,Antonio Vena,Carmen Di Grazia,Anna Maria Raiola,Federica Portunato,Chiara Dentone,Denise Battaglini,Lorenzo Ball,Chiara Robba,Emanuele Angelucci,Iole Brunetti,Matteo Bassetti
DOI: https://doi.org/10.1093/jac/dkae037
2024-02-15
Journal of Antimicrobial Chemotherapy
Abstract:Abstract Background Isavuconazole is first-line treatment of invasive aspergillosis. Therapeutic drug monitoring (TDM) is deemed not necessary, since most patients reached therapeutic levels (>1 mg/L) in large studies. Low levels were reported in some critically ill patients admitted to the ICU. The aim was to compare isavuconazole levels between critically ill and non-critically ill patients. Materials and methods Retrospective analysis of data from all patients treated with standard-dose isavuconazole between 1 January 2019 and 26 October 2022 was performed. The following data were collected: TDM results from the first 30 days of therapy; ward of admission; demographic and clinical characteristics; continuous renal replacement therapy; extracorporeal membrane oxygenation; and co-administered drugs. Results Seventy-two patients (median age 65 years) and 188 TDM measurements (mean number of samples per patient 2.6 ± 1.7) were included; 33 (45.8%) were ICU patients (3 also had haematological disorders); 39 (54.2%) were non-ICU patients, of whom 31 had haematological disorders. In all patients, the mean isavuconazole blood level was 3.33 ± 2.26 mg/L. Significantly lower levels were observed in the ICU versus the non-ICU population: mean 2.02 ± 1.22 versus 4.15 ± 2.31 mg/L (P < 0.001). Significantly higher rates of subtherapeutic levels were observed in ICU patients compared with the non-ICU population: all determinations <2 mg/L in 33.3% versus 7.7%, and all determinations <1 mg/L in 12.1% versus 0%, respectively. Predictors of lower isavuconazole levels were admission to the ICU, BMI > 25 kg/m2, bilirubin > 1.2 mg/dL and the absence of haematological disorder. Conclusions ICU patients had significantly lower isavuconazole blood levels compared to non-ICU population. The TDM of isavuconazole for efficacy should be performed in ICU.
pharmacology & pharmacy,infectious diseases,microbiology